Geode Capital Management’s Adicet Bio ACET Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $689K | Buy |
101,135
+12,279
| +14% | +$91.9K | ﹤0.01% | 3474 |
|
|
2025
Q4 | $748K | Buy |
88,856
+44,710
| +101% | +$494K | ﹤0.01% | 3461 |
|
|
2025
Q3 | $572K | Hold |
44,146
| – | – | ﹤0.01% | 3568 |
|
|
2025
Q2 | $431K | Sell |
44,146
-4,023
| -8% | -$42.4K | ﹤0.01% | 3600 |
|
|
2025
Q1 | $582K | Buy |
48,169
+198
| +0.4% | +$2.83K | ﹤0.01% | 3491 |
|
|
2024
Q4 | $739K | Sell |
47,971
-64
| -0.1% | -$1.21K | ﹤0.01% | 3473 |
|
|
2024
Q3 | $1.11M | Buy |
48,035
+6,098
| +15% | +$137K | ﹤0.01% | 3318 |
|
|
2024
Q2 | $812K | Sell |
41,937
-33,373
| -44% | -$894K | ﹤0.01% | 3389 |
|
|
2024
Q1 | $2.83M | Buy |
75,310
+33,948
| +82% | +$1.4M | ﹤0.01% | 2974 |
|
|
2023
Q4 | $1.25M | Buy |
41,362
+1,802
| +5% | +$39.3K | ﹤0.01% | 3263 |
|
|
2023
Q3 | $867K | Sell |
39,560
-1
| -0% | -$35 | ﹤0.01% | 3386 |
|
|
2023
Q2 | $1.54M | Buy |
39,561
+1,674
| +4% | +$148K | ﹤0.01% | 3196 |
|
|
2023
Q1 | $3.49M | Buy |
37,887
+1,002
| +3% | +$126K | ﹤0.01% | 2793 |
|
|
2022
Q4 | $5.28M | Buy |
36,885
+3,229
| +10% | +$806K | ﹤0.01% | 2636 |
|
|
2022
Q3 | $7.66M | Buy |
33,656
+7,308
| +28% | +$1.85M | ﹤0.01% | 2433 |
|
|
2022
Q2 | $6.15M | Buy |
26,348
+1,858
| +8% | +$408K | ﹤0.01% | 2584 |
|
|
2022
Q1 | $7.82M | Buy |
24,490
+5,207
| +27% | +$1.2M | ﹤0.01% | 2508 |
|
|
2021
Q4 | $5.4M | Sell |
19,283
-1,927
| -9% | -$331K | ﹤0.01% | 2855 |
|
|
2021
Q3 | $2.66M | Buy |
21,210
+1,314
| +7% | +$163K | ﹤0.01% | 3234 |
|
|
2021
Q2 | $3.27M | Buy |
19,896
+12,439
| +167% | +$2.53M | ﹤0.01% | 3119 |
|
|
2021
Q1 | $1.56M | Buy |
7,457
+5,365
| +256% | +$1.23M | ﹤0.01% | 3375 |
|
|
2020
Q4 | $470K | Buy |
2,092
+291
| +16% | +$59.6K | ﹤0.01% | 3609 |
|
|
2020
Q3 | $342K | Sell |
1,801
-40
| -2% | -$10.1K | ﹤0.01% | 3555 |
|
|
2020
Q2 | $443K | Sell |
1,841
-1,266
| -41% | -$249K | ﹤0.01% | 3416 |
|
|
2020
Q1 | $358K | Buy |
3,107
+129
| +4% | +$19.1K | ﹤0.01% | 3363 |
|
|
2019
Q4 | $496K | Buy |
2,978
+1,076
| +57% | +$545K | ﹤0.01% | 3505 |
|
|
2019
Q3 | $1.88M | Buy |
1,902
+126
| +7% | +$141K | ﹤0.01% | 2973 |
|
|
2019
Q2 | $2.03M | Buy |
1,776
+969
| +120% | +$878K | ﹤0.01% | 2942 |
|
|
2019
Q1 | $616K | Buy |
807
+35
| +5% | +$31.8K | ﹤0.01% | 3349 |
|
|
2018
Q4 | $745K | Buy |
772
+139
| +22% | +$183K | ﹤0.01% | 3229 |
|
|
2018
Q3 | $1.07M | Buy |
633
+50
| +9% | +$65.2K | ﹤0.01% | 3193 |
|
|
2018
Q2 | $597K | Buy |
583
+86
| +17% | +$92.6K | ﹤0.01% | 3376 |
|
|
2018
Q1 | $532K | Buy |
+497
| New | +$912K | ﹤0.01% | 3373 |
|
Other funds holding ACET
RCM
O
VCM
WP
PM
SCM
Geode Capital Management's ACET Position: Q1 2026 in Review
Geode Capital Management increased its Adicet Bio (ACET) stake by 14% in Q1 2026, buying an estimated $91.9K and bringing the position to 101,135 shares worth $689K. The position accounts for ﹤0.01% of the portfolio, ranked #3474.
Geode Capital Management first reported a position in ACET in Q1 2018 and has held it in 33 quarters since. The position peaked at $7.82M in Q1 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.
- Geode Capital Management held 101,135 shares of Adicet Bio worth $689K as of Q1 2026.
- Geode Capital Management bought 12,279 Adicet Bio shares in Q1 2026, an estimated $91.9K.
- Adicet Bio made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3474 holding.
- Geode Capital Management first reported a position in Adicet Bio in Q1 2018 and has held it in 33 quarters since.
- Geode Capital Management's Adicet Bio position peaked at $7.82M in Q1 2022.
- 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.